Comparison of albendazole cytotoxicity in terms of metabolite formation in four model systems

1. Baillie T.A.: Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem Res Toxicol 2008, 21, 129-137.10.1021/tx7002273Search in Google Scholar

2. Baliharová V., Skálová L., Maas R.F.M., De Vrieze G., Bull S., Fink-Gremmels J.: The effects of benzimidazole anthelmintics on P4501A in rat hepatocytes and HepG2 cells. Res Vet Sci 2003, 75, 61-69.10.1016/S0034-5288(03)00033-XOpen DOISearch in Google Scholar

3. Capece B.P.S., Navarro M., Arcalis T., Castells G., Toribio L., Perez F., Carretero A., Ruberte J., Arboix M., Cristòfol C.: Albendazole sulphoxide enantiomers in pregnant rats embryo concentrations and developmental toxicity. Vet J 2003, 165, 266-275.10.1016/S1090-0233(02)00158-2Search in Google Scholar

4. Capece B.P.S., Virkel G.L., Lanusse C.E.: Enantiomeric behaviour of albendazole and fenbendazole sulfoxides in domestic animals: pharmacological implications. Vet J 2009, 181, 241-250.10.1016/j.tvjl.2008.11.01019124257Search in Google Scholar

5. Capleton A.C., Courage C., Rumsby P., Holmes P., Stutt E., Boxall B.A., Levy L.S.: Prioritising veterinary medicines according to their potential indirect human exposure and toxicity profile. Toxicol Lett 2006, 163, 213-223.10.1016/j.toxlet.2005.10.02316513297Search in Google Scholar

6. Castell J.V., Jover R., Martinez-Jiménez C.P., Gómez- Lechón M.J.: Hepatocyte cell lines: their use, scope, and limitations in drug metabolism studies. Expert Opin Drug Metab Toxicol 2006, 2, 183-212.10.1517/17425255.2.2.18316866607Search in Google Scholar

7. Coecke S., Ahr H., Blaauboer B.J., Bremer S., Castell J., Combes R., Corvi R., Crespi C.L., Cunningham M.L., Elaut G., Eletti B., Freidiq A., Gennari A., Ghersi-Egea J.F., Guillouzo A., Hartung T., Hoet P., Ingelman-Sundberg M., Munn S., Janssens W., Ladstetter B., Leahy D., Long A., Meneguz A., Monshouwer M., Morath S., Nagelkerke F., Pelkonen O., Ponti J., Prieto P., Richert L., Sabbioni E., Schaack B., Steiling W., Testai E., Vericat J.A., Worth A.: Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM Workshop 54. Altern Lab Anim 2006, 34, 49-84.10.1177/02611929060340011316522150Search in Google Scholar

8. Cristòfol C., Navarro M., Franquelo C., Valladares J.E., Carretero A., Ruberte J., Arboix M.: Disposition of netobimin, albendazole, and its metabolites in the pregnant rat: developmental toxicity. Toxicol Appl Pharmacol 1997, 144, 56-61. 9. Dayan A.D.: Albendazole, mebendazole, and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop 2003, 86, 141-159. 10.1006/taap.1997.81149169069Search in Google Scholar

10. Delatour P., Benoit E., Besse S., Boukraa A.: Comparative enantioselectivity in the sulphoxidation of albendazole in man, dogs, and rats. Xenobiotica 1991, 21, 217-221.10.3109/004982591090394632058177Search in Google Scholar

11. Delatour P., Benoit E., Caude M., Tambute A.: Species differences in the generation of the chiral sulfoxide metabolite of albendazole in sheep and rats. Chirality 1990, 2, 156-160.10.1002/chir.5300203062147560Open DOISearch in Google Scholar

12. Delatour P.: Some aspects of the teratogenicity of veterinary drugs. Vet Res Commun 1983, 7, 125-131.10.1007/BF02228606Open DOISearch in Google Scholar

13. Donato M.T., Jover R., Gómez- Lechón M.J.: Hepatic cell lines for drug hepatotoxicity testing: limitations and strategies to upgrade their metabolic competence by gene engineering. Curr Drug Metab 2013, 14, 946-968.10.2174/1389200211314090002Open DOISearch in Google Scholar

14. Donato M.T., Lahoz A., Castell J.V., Gómez-Lechón M.J.: Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab 2008, 9, 1-11.10.2174/138920008783331086Search in Google Scholar

15. European Medicines Evaluation Agency (EMEA). Albendazole (Extrapolation to all ruminants) Summary Report. EMEA/MRL/865/03-Final. 2004. Available from: http://www.emea.eu.int.Search in Google Scholar

16. Gad S.C.: Active drug metabolites in drug development. Curr Opin Pharmacol 2003, 3, 98-100.10.1016/S1471-4892(02)00003-6Search in Google Scholar

17. Hennessy D.R., Sangster N.C., Steel J.W., Collins G.H.: Comparative pharmacokinetic behavior of albendazole in sheep and goats. Int J Parasitol 1993, 23, 321-325.10.1016/0020-7519(93)90006-KOpen DOISearch in Google Scholar

18. Křižová-Forstová V., Lamka J., Cvilink V., Hanušová V., Skálová L.: Factors affecting pharmacokinetics of benzimidazole anthelmintics in food-producing animals: the consequences and potential risks. Res Vet Sci 2011, 91, 333-341.10.1016/j.rvsc.2010.12.013Open DOISearch in Google Scholar

19. Mosmann T.: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65, 55-63.10.1016/0022-1759(83)90303-4Open DOISearch in Google Scholar

20. Radko L., Minta M., Stypuła-Trębas S.: Differential toxicities of albendazole and its two main metabolites to Balb/c 3T3, HepG2, FaO lines and rat hepatocytes. J Vet Res 2016, 60, 495-502.10.1515/jvetres-2016-0073Search in Google Scholar

21. Rodriges R.M., Bouhifd M., Bories G., Sacco M.G., Gribaldo L., Fabbri M., Coecke S., Whelan M.P.: Assessment of an automated in vitro basal cytotoxicity test system based on metabolically-competent cells. Toxicol in Vitro 2013, 27, 760-767.10.1016/j.tiv.2012.12.00423261643Open DOISearch in Google Scholar

22. Rolin S., Souhaili-el Amri H., Batt A.M., Levy M., Bagrel D., Siest G.: Study of the in vitro bioactivation of albendazole in human liver microsomes and hepatoma cell lines. Cell Biol Toxicol 1989, 5, 1-14.10.1007/BF001410602563953Open DOISearch in Google Scholar

23. Schoonen W.G.E.J., de Roos J.A.D.M., Westerink W.M.A., Débiton E.: Cytotoxic effects of 110 reference compounds on HepG2 cells and for 60 compounds on HeLa, ECC-1, and CHO cells. II Mechanistic assays on NAD(P)H, ATP and DNA contents. Toxicol in Vitro 2005, 19, 491-503.10.1016/j.tiv.2005.01.002Search in Google Scholar

24. Schoonen W.G.E.J., Westerink W.M.A., de Roos J.A.D.M., Débiton E.: Cytotoxic effects of 100 reference compounds on HepG2 and HeLa cells and of 60 compounds on ECC-1 and CHO cells. I Mechanistic assays on ROS, glutathione depletion, and calcein uptake. Toxicol in Vitro 2005, 19, 505-516.10.1016/j.tiv.2005.01.003Search in Google Scholar

25. Seglen P.O.: Preparation of isolation rat liver cells. Methods Cell Biol 1976, 13, 29-83.10.1016/S0091-679X(08)61797-5Search in Google Scholar

26. Teruel M.T., Felipe A.E., Solana H.D., Sallovitz J.M., Lanusse C.E.: Placental and fetal toxicity of albendazole sulphoxide in Wistar rats. Vet Hum Toxicol 2003, 45, 131-136. Search in Google Scholar

27. The Joint FAO/WHO Committee on Food Additives (JECFA). Albendazole: in Evaluation of Certain Veterinary Drug Residues in Food. Thirty-fourth Report of the Joint WHO/FAO Expert Committee on Food Additive, WHO, Geneva, 1989, pp. 14-19. Available from: http://apps.who.int/food-additives-contaminantsjecfa-database/chemical.aspx?chemID=478Search in Google Scholar

28. Wang K., Shindoh H., Inoue T., Horii I.: Advantages of in vitro cytotoxicity testing by using primary rat hepatocytes in comparison with established cell lines. J Toxicol Sci 2002, 27, 229-237.10.2131/jts.27.22912238146Open DOISearch in Google Scholar

29. Wilk-Zasadna I., Bernasconi C., Pelkonen O., Coecke S.: Biotransformation in vitro: an essential consideration in the quantitative in vitro-to-in vivo extrapolation (QIVIVE) of toxicity data. Toxicology 2015, 332, 8-19.10.1016/j.tox.2014.10.00625456264Search in Google Scholar